Marc Stapley - Glaukos Corp Independent Director
| GKOS Stock | USD 142.69 1.96 1.39% |
Director
Mr. Marc A. Stapley serves as an Independent Director of the Company. Mr. Stapley is currently the executive vice president, strategy and corporate development, for Illumina, Inc. Previously, Mr. Stapley served as Illumina chief administrative officer with responsibility for all general and administrative functions. Prior to that, he served as senior vice president and chief financial officer of Illumina. He is also a member of Illuminas executive management team, which is responsible for directing all aspects of the companys strategy, planning and operations. Before joining Illumina, from 2009 to 2012, Mr. Stapley was senior vice president, finance at Pfizer Inc. and was responsible for global financial processes and systems, leading integration efforts in both the Wyeth Ltd. and King Pharmaceutical, Inc. acquisitions and providing oversight to the companys largest technology investment program. Prior to Pfizer, he served in a variety of senior finance roles at AlcatelLucent, including Americas chief financial officer. He also worked as finance director and controller for several groups at Cadence Design Systems, Inc. Mr. Stapley is currently a member of the board of directors of Helix, Illumina consumer genomics venture. Mr. Stapley began his career as an Auditor at Coopers Lybrand. He holds a First Class B.Sc. from The University of Reading and is a member of the Institute of Chartered Accountants in England and Wales. since 2014.
| Age | 50 |
| Tenure | 10 years |
| Address | One Glaukos Way, Aliso Viejo, CA, United States, 92656 |
| Phone | 949 367 9600 |
| Web | https://www.glaukos.com |
Latest Insider Transactions
Marc Stapley Latest Insider Activity
Tracking and analyzing the buying and selling activities of Marc Stapley against Glaukos Corp stock is an integral part of due diligence when investing in Glaukos Corp. Marc Stapley insider activity provides valuable insight into whether Glaukos Corp is net buyers or sellers over its current business cycle. Note, Glaukos Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell Glaukos Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Marc Stapley over six months ago Disposition of 6250 shares by Marc Stapley of Glaukos Corp at 32.0 subject to Rule 16b-3 | ||
Marc Stapley over six months ago Disposition of 5971 shares by Marc Stapley of Veracyte at 21.1 subject to Rule 16b-3 | ||
Marc Stapley over six months ago Disposition of 13286 shares by Marc Stapley of Veracyte at 24.0 subject to Rule 16b-3 | ||
Marc Stapley over six months ago Payment of 3203 shares by Marc Stapley of Veracyte subject to Rule 16b-3 |
Glaukos Corp Management Efficiency
The company has return on total asset (ROA) of (0.0774) % which means that it has lost $0.0774 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.261) %, meaning that it created substantial loss on money invested by shareholders. Glaukos Corp's management efficiency ratios could be used to measure how well Glaukos Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2024. Return On Capital Employed is likely to drop to -0.16 in 2024. At this time, Glaukos Corp's Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 22.4 M in 2024, whereas Other Assets are likely to drop slightly above 15.3 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Brian Concannon | CONMED | 62 | |
| Fred Hite | Orthopediatrics Corp | 56 | |
| Susan Siegel | Nevro Corp | 60 | |
| Brad Vale | Nevro Corp | 67 | |
| Jean Hobby | Integer Holdings Corp | 60 | |
| James Hinrichs | Integer Holdings Corp | 53 | |
| Donald Spence | Integer Holdings Corp | 67 | |
| Michael DeMane | Nevro Corp | 63 | |
| Elizabeth Weatherman | Nevro Corp | 60 | |
| Jerome Lande | CONMED | 45 | |
| John Workman | CONMED | 69 | |
| David Bronson | CONMED | 67 | |
| Joel Suiter | SurModics | N/A | |
| Frank Fischer | Nevro Corp | 78 | |
| Martin Maxwell | Integer Holdings Corp | 62 | |
| Kristina Wright | Paragon 28 | 47 | |
| Shawn McCormick | Nevro Corp | 56 | |
| Cheryl Capps | Integer Holdings Corp | 59 | |
| Sheila Antrum | Integer Holdings Corp | 62 | |
| Martha Aronson | CONMED | 53 | |
| Pamela Bailey | Integer Holdings Corp | 72 | |
Management Performance
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.0774 |
Glaukos Corp Leadership Team
Elected by the shareholders, the Glaukos Corp's board of directors comprises two types of representatives: Glaukos Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Glaukos. The board's role is to monitor Glaukos Corp's management team and ensure that shareholders' interests are well served. Glaukos Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Glaukos Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gilbert Kliman, Independent Director | ||
| Leana Wen, Independent Director | ||
| L Katz, Chief Medical Officer | ||
| Thomas Burns, Chairman of the Board, President, Chief Executive Officer | ||
| Diane Biagianti, Sr Counsel | ||
| David Haffner, VP Technologies | ||
| Mark Foley, Lead Independent Director | ||
| Joseph Gilliam, Chief Financial Officer, Senior Vice President - Corporate Development | ||
| Alex Thurman, Chief Financial Officer, Senior Vice President | ||
| Aimee Weisner, Independent Director | ||
| Mory Gharib, CoFounder | ||
| Michele Allegretto, Senior Resources | ||
| Robert Davis, General VP | ||
| David Hoffmeister, Independent Director | ||
| Denice Torres, Independent Director | ||
| Tracy Founds, Senior Safety | ||
| William Link, Independent Chairman of the Board | ||
| Chris Calcaterra, Chief Commercial Officer | ||
| Christopher Lewis, Vice Affairs | ||
| Diana Scherer, VP Counsel | ||
| Tomas Navratil, Chief Development Officer | ||
| MD FACS, Chief Officer | ||
| Jane Rady, Senior Development | ||
| Robert JD, General VP | ||
| Marc Stapley, Independent Director |
Glaukos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Glaukos Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.0774 | ||||
| Profit Margin | (0.42) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 7.76 B | ||||
| Shares Outstanding | 55.14 M | ||||
| Shares Owned By Insiders | 3.19 % | ||||
| Shares Owned By Institutions | 96.81 % | ||||
| Number Of Shares Shorted | 2.81 M | ||||
| Price To Earning | 94.70 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Glaukos Stock Analysis
When running Glaukos Corp's price analysis, check to measure Glaukos Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Glaukos Corp is operating at the current time. Most of Glaukos Corp's value examination focuses on studying past and present price action to predict the probability of Glaukos Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Glaukos Corp's price. Additionally, you may evaluate how the addition of Glaukos Corp to your portfolios can decrease your overall portfolio volatility.